Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 6HR+/HER2- Advanced Breast Cancer 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Breast Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

aflutinib 3Saline Solution 3Radiotherapy 3Temozolomide 2Receptors, Interleukin-8B 2Radiosurgery 2Pemetrexed 2Memantine 2Indocyanine Green 2Dexmedetomidine 2Cyclophosphamide 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2Aminolevulinic Acid 2urinastatin 1trastuzumab deruxtecan 1tovorafenib 1sacituzumab govitecan 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1neratinib 1montelukast 1gallium maltolate 1fludarabine 1dalpiciclib 1asciminib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Brain Neoplasms × dalpiciclib × Clear all
NCT07539753 2026-04-30

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Nanfang Hospital, Southern Medical University

Phase 2 Not yet recruiting
46 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡